Lauren Griggs
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Lauren Griggs has a total of 23 co-authors. Here are the top co-authors by number of shared publications:
Aaron Mattingly
The Pennsylvania State University
1 shared publication- Ambra Pozzi
Division of Nephrology and Hypertension, Department of Medicine, Vanderbilt University Medical Center, Nashville, Tennessee
1 shared publication - Christopher A. Johnson
Department of Biomedical Engineering, Vanderbilt University, Nashville, TN 37235, USA
1 shared publication - Christopher A. Lemmon
Department of Biomedical Engineering, Virginia Commonwealth University, Richmond, USA
1 shared publication Christopher Dancy
The Pennsylvania State University, University Park
1 shared publication- Cynthia A. Reinhart-King
Department of Bioengineering, Rice University, Houston, USA
1 shared publication
Latest Publications
- 21 August 2025
- Published by American Society for Engineering Education
WIP: Introducing Research in Summer Bridge Programs
- 21 August 2025
- Published by American Society for Engineering Education
WIP: Introducing Research in Summer Bridge Programs
- 2 April 2024
- Published by American Society for Engineering Education
Peru in State College
- Open Access
- 3 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6679
Spatial Gradients of E-Cadherin and Fibronectin in TGF-β1-Treated Epithelial Colonies Are Independent of Fibronectin Fibril Assembly
Epithelial to Mesenchymal Transition (EMT) is a dynamic, morphogenetic process characterized by a phenotypic shift in epithelial cells towards a motile and often invasive mesenchymal phenotype. We have previously demonstrated that EMT is associated with an increase in assembly of the extracellular matrix protein fibronectin (FN) into insoluble, viscoelastic fibrils. We have also demonstrated that Transforming Growth Factor-1 (TGF-1) localizes to FN fibrils, and disruption of FN assembly or disruption of TGF-1 localization to FN fibrils attenuates EMT. Previous studies have shown that TGF-1 induces spatial gradients of EMT in mammary epithelial cells cultured on FN islands, with cells at free edges of the island preferentially undergoing EMT. In the current work, we sought to investigate: (a) whether FN fibril assembly is also spatially patterned in response to TGF-1, and (b) what effects FN fibril inhibition has on spatial gradients of E-Cadherin and FN fibrillogenesis. We demonstrate that mammary epithelial cells cultured on square micropatterns have fewer E-Cadherin-containing adherens junctions and assemble more FN fibrils at the periphery of the micropattern in response to increasing TGF-1 concentration, indicating that TGF-1 induces a spatial gradient of both E-Cadherin and FN fibrils. Inhibition of FN fibril assembly globally diminished E-Cadherin-containing adherens junctions and FN fibrillogenesis, but did not eliminate the spatial gradient of either. This suggests that global inhibition of FN reduces the degree of both FN fibrillogenesis and E-Cadherin-containing adherens junctions, but does not eliminate the spatial gradient of either, suggesting that spatial gradients of EMT and FN fibrillogenesis are influenced by additional factors.- 3 April 2023
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 24 (7) , 6679
Open AccessSpatial Gradients of E-Cadherin and Fibronectin in TGF-β1-Treated Epithelial Colonies Are Independent of Fibronectin Fibril Assembly
Epithelial to Mesenchymal Transition (EMT) is a dynamic, morphogenetic process characterized by a phenotypic shift in epithelial cells towards a motile and often invasive mesenchymal phenotype. We have previously demonstrated that EMT is associated with an increase in assembly of the extracellular matrix protein fibronectin (FN) into insoluble, viscoelastic fibrils. We have also demonstrated that Transforming Growth Factor-1 (TGF-1) localizes to FN fibrils, and disruption of FN assembly or disruption of TGF-1 localization to FN fibrils attenuates EMT. Previous studies have shown that TGF-1 induces spatial gradients of EMT in mammary epithelial cells cultured on FN islands, with cells at free edges of the island preferentially undergoing EMT. In the current work, we sought to investigate: (a) whether FN fibril assembly is also spatially patterned in response to TGF-1, and (b) what effects FN fibril inhibition has on spatial gradients of E-Cadherin and FN fibrillogenesis. We demonstrate that mammary epithelial cells cultured on square micropatterns have fewer E-Cadherin-containing adherens junctions and assemble more FN fibrils at the periphery of the micropattern in response to increasing TGF-1 concentration, indicating that TGF-1 induces a spatial gradient of both E-Cadherin and FN fibrils. Inhibition of FN fibril assembly globally diminished E-Cadherin-containing adherens junctions and FN fibrillogenesis, but did not eliminate the spatial gradient of either. This suggests that global inhibition of FN reduces the degree of both FN fibrillogenesis and E-Cadherin-containing adherens junctions, but does not eliminate the spatial gradient of either, suggesting that spatial gradients of EMT and FN fibrillogenesis are influenced by additional factors. - Open Access
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (46) , eabo1673
Diabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening
Diabetes mellitus is a complex metabolic disorder that is associated with an increased risk of breast cancer. Despite this correlation, the interplay between tumor progression and diabetes, particularly with regard to stiffening of the extracellular matrix, is still mechanistically unclear. Here, we established a murine model where hyperglycemia was induced before breast tumor development. Using the murine model, in vitro systems, and patient samples, we show that hyperglycemia increases tumor growth, extracellular matrix stiffness, glycation, and epithelial-mesenchymal transition of tumor cells. Upon inhibition of glycation or mechanotransduction in diabetic mice, these same metrics are reduced to levels comparable with nondiabetic tumors. Together, our study describes a novel biomechanical mechanism by which diabetic hyperglycemia promotes breast tumor progression via glycating the extracellular matrix. In addition, our work provides evidence that glycation inhibition is a potential adjuvant therapy for diabetic cancer patients due to the key role of matrix stiffening in both diseases.
- 16 November 2022
- Published by American Association for the Advancement of Science (AAAS) in Science Advances
- Vol. 8 (46) , eabo1673
Open AccessDiabetic hyperglycemia promotes primary tumor progression through glycation-induced tumor extracellular matrix stiffening
Diabetes mellitus is a complex metabolic disorder that is associated with an increased risk of breast cancer. Despite this correlation, the interplay between tumor progression and diabetes, particularly with regard to stiffening of the extracellular matrix, is still mechanistically unclear. Here, we established a murine model where hyperglycemia was induced before breast tumor development. Using the murine model, in vitro systems, and patient samples, we show that hyperglycemia increases tumor growth, extracellular matrix stiffness, glycation, and epithelial-mesenchymal transition of tumor cells. Upon inhibition of glycation or mechanotransduction in diabetic mice, these same metrics are reduced to levels comparable with nondiabetic tumors. Together, our study describes a novel biomechanical mechanism by which diabetic hyperglycemia promotes breast tumor progression via glycating the extracellular matrix. In addition, our work provides evidence that glycation inhibition is a potential adjuvant therapy for diabetic cancer patients due to the key role of matrix stiffening in both diseases.